Inclusion Criteria
* Fever \> 38°C for \< 48 hours and clinical presentation consistent with dengue fever.
* Positive NS1 strip assay or reverse-transcriptase polymerase chain reaction (RT-PCR) assay for dengue virus.
* Informed consent form signed and dated by the patient.
* Subject able to give informed consent and able to comply with all study visits and all study procedures.
* Females of childbearing potential should be using and committed to continue using acceptable birth control methods.
* Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or
* Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or
* Stable hormonal contraception for at least 3 months prior to study through study completion; or
* Surgical sterilization (vasectomy) of male partner at least 6 months prior to study.
* To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses.
Exclusion Criteria
* One or more of the following dengue warning signs and symptoms:
* Intense and continuous abdominal pain (referred pain or on palpation);
* Persistent vomiting;
* Fluid accumulation (ascites, pleural effusion, or pericardial effusion);
* Postural hypotension and/or collapse;
* Painful hepatomegaly \> two centimeters below the right costal margin;
* Mucosal bleeding;
* Major bleeding (hematemesis and/or melena);
* Lethargy and/or irritability;
* Diminished urine output;
* Hypothermia;
* Progressive increase in hematocrit or 20% above baseline or normal for age;
* Abrupt drop in platelets;
* Respiratory discomfort.
* One or more of the following signs and symptoms of severe dengue, such as:
* Severe plasma extravasation, leading to shock evidenced by one or more of the following:
* Tachycardia;
* Cold distal extremities;
* Weak, thready pulse;
* Slow capillary refill (\> 2 seconds);
* Pulse pressure \< 20 mmHg;
* Tachypnea; or
* Oliguria (\<1.5 mL/kg/hr).
* Systolic blood pressure \< 90 mmHg or decrease \>40 mmHg;
* Cyanosis;
* Fluid accumulation with respiratory discomfort;
* Severe bleeding; or
* Severe organ impairment, evidenced by one or more of the following:
* Liver impairment (AST \>1000 U/L, international normalized ratio \>1.5);
* Renal impairment (serum creatinine ≥1.5 mg/dL); or
* Myocarditis, pericarditis, or clinical heart failure (by chest x-ray, echocardiography, electrocardiogram, or cardiac enzymes if available).
* Female who is pregnant, lactating or of childbearing potential.
* Self-reported or suspected congenital or acquired immunodeficiency (including HIV infection); or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the previous 3 months).
* Prior vaccination against dengue fever.
* Significant chronic illness that, in the opinion of the Investigator, would interfere with study validity, conduct or completion.
